Board Meeting Outcome for The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended June 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Remedium Lifecare Limited (formerly Roxy Exports Limited, BSE scrip 539561) approved its Q1 FY26 unaudited results on August 4, 2025. On a standalone basis, revenue from operations fell sharply to ₹1,837.37 lakhs versus ₹7,769.62 lakhs in Q1 FY25, a drop of roughly 76%. The company slipped into a loss before and after tax of ₹(36.51) lakhs, compared to a profit of ₹163.60 lakhs in the year-ago quarter. On a consolidated basis, revenue was ₹11,336.67 lakhs with a profit after tax of ₹464.88 lakhs, lifted mainly by the subsidiary Remlife Global PTE (Singapore). The statutory auditors Taori Sandeep & Associates issued an unmodified limited review report on the standalone and consolidated numbers, though the subsidiary's figures were not reviewed by its own auditor and were furnished only by management.
Standalone results are weak – a steep revenue fall and a return to loss signal operational pressure at the parent level, which is negative for shareholders. However, the consolidated picture is propped up by the Singapore subsidiary whose financials are unaudited/reviewed only by management, so the headline consolidated profit should be read with some caution.